Adversarial Injection · Zanubrutinib (Brukinsa; CAS 1691249-44-1; (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxamide [CAS registry name; MW 471.54 g/mol; C27H29N5O2; imidazo[4,5-c]pyridine core + 4-phenoxyphenyl + acryloylpiperidine arm]; imidazo[4,5-c]pyridine-piperidine-acrylamide scaffold [FIRST imidazo[4,5-c]pyridine ring system in Glyphward portfolio; THIRD BTK Cys481 acrylamide warhead — ibrutinib #499 [phenylaminopyrimidine acrylamide] + acalabrutinib #512 [imidazo[1,5-a]pyrazine propiolamide/but-2-ynoyl] + zanubrutinib #513 [imidazo[4,5-c]pyridine acrylamide] — three independent covalent Cys481 warhead chemistries with zero OEL in all EHS platforms]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · THIRD BTK Inhibitor in Glyphward Portfolio (BTK class OEL absence confirmed across THREE independent NDA holders: ibrutinib [AbbVie/Janssen NDA 205552] + acalabrutinib [AstraZeneca NDA 210259] + zanubrutinib [BeiGene NDA 213756]) + FIRST BeiGene-Originated TKI (FIRST non-US-origin oncology company NDA holder in Glyphward portfolio — BeiGene [Beijing Genomics Institute spin-off; headquartered Beijing/San Mateo; NASDAQ: BGNE]; first Chinese pharmaceutical company NDA null in 512-attack portfolio) + BTK TRIPLE-CLASS NULL (SECOND three-NDA-holder mechanism-class null in Glyphward portfolio [after rucaparib/PARP three-NDA-holder null Attack #510]; BTK is now confirmed with zero OEL at three independent companies, three independent EHS platforms) · Attack #513

Zanubrutinib ((S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxamide; Brukinsa; CAS 1691249-44-1; MW 471.54 g/mol; C27H29N5O2; imidazo[4,5-c]pyridine bicycle [FIRST imidazo[4,5-c]pyridine in Glyphward portfolio; prior imidazo structures: acalabrutinib uses imidazo[1,5-a]pyrazine [Attack #512; different ring fusion]; zanubrutinib imidazo[4,5-c]pyridine is a [4,5-c] pyridine-fused imidazole; structurally and pharmacologically distinct from acalabrutinib's [1,5-a]pyrazine] + 4-phenoxyphenyl aryl + acryloylpiperidine arm [THIRD BTK Cys481 covalent warhead in Glyphward portfolio: ibrutinib #499 phenylaminopyrimidine + acrylamide → Cys481; acalabrutinib #512 imidazo[1,5-a]pyrazine + but-2-ynoyl propiolamide → Cys481; zanubrutinib #513 imidazo[4,5-c]pyridine + acryloylpiperidine acrylamide → Cys481; three structurally independent warhead scaffolds; three independent covalent Cys481 adducts; three independent EHS null records]; MECHANISM: HIGHLY SELECTIVE IRREVERSIBLE BTK INHIBITOR — THIRD BTK inhibitor in Glyphward portfolio; BTK IC50 ~0.5 nM [potent; comparable to ibrutinib]; improved selectivity profile vs ibrutinib [>300 kinases tested; zanubrutinib more selective than ibrutinib across ITK, EGFR, JAK3, TEC]; designed specifically to minimize off-target kinase activity while maintaining full BTK Cys481 occupancy; BTK OCCUPANCY: zanubrutinib was designed to achieve maximum BTK occupancy in peripheral blood mononuclear cells and lymph node tissue [key pharmacodynamic principle: complete BTK occupancy correlates with clinical response; ibrutinib incomplete occupancy in lymph nodes → zanubrutinib redesigned for improved lymphoid tissue penetration]; TRIPLE-NDA-HOLDER BTK CLASS NULL: ibrutinib [AbbVie/Janssen NDA 205552] + acalabrutinib [AstraZeneca NDA 210259] + zanubrutinib [BeiGene NDA 213756] = SECOND three-NDA-holder mechanism-class null in Glyphward portfolio [after PARP: olaparib/niraparib/rucaparib Attacks #501/507/510]; BTK class is now confirmed with zero OEL across three independent companies, three independent corporate EHS systems, three independent FDA NDA filings; FIRST BEIGENE NDA NULL: BeiGene [Beijing Genomics Institute origin; founded 2010; Beijing headquarters; San Mateo CA US headquarters; dual-listed NYSE/HKEx] — FIRST Chinese-origin pharmaceutical company NDA null in the 512-attack Glyphward portfolio; prior Glyphward portfolio restricted to US/European companies [AbbVie; AstraZeneca; Pfizer; Novartis; Roche/Genentech; BMS; Amgen; Bayer; GSK]; zanubrutinib introduces the first non-US-origin global oncology company with an independent NIOSH HD Category 1 null record; GEOGRAPHY OF EHS NULL RECORDS: US-centric EHS platforms [Cority; VelocityEHS; EHS Insight] were designed around US OSHA regulatory framework; BeiGene US operations apply US OSHA standards via Cority while maintaining Chinese regulatory filing independently; no cross-reference between BeiGene Chinese EHS framework and US EHS platform; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — BeiGene San Mateo CA (Brukinsa NDA 213756 holder; US commercial headquarters), Lonza Conshohocken PA (zanubrutinib API and tablet contract manufacturer), and UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA (CLL/MCL hematology program; BTK triple-class dispensing corridor) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRD BTK Inhibitor + BTK Triple-NDA-Holder Class Null + FIRST BeiGene NDA: AI Prompt Injection via EHS Monitor Report AI

Zanubrutinib (CAS 1691249-44-1; NIOSH HD Category 1) is the third BTK inhibitor in the Glyphward portfolio, completing the BTK triple-NDA-holder class null. Ibrutinib (Attack #499; AbbVie/Janssen NDA 205552), acalabrutinib (Attack #512; AstraZeneca NDA 210259), and zanubrutinib (Attack #513; BeiGene NDA 213756) represent three independent BTK inhibitors across three independent companies, three independent EHS platforms, three independent NIOSH HD Category 1 null records, and three independent covalent Cys481 warhead chemistries — all returning zero OEL. Zanubrutinib introduces the first BeiGene-originated TKI in the portfolio and the first non-US-origin pharmaceutical company NDA null, exposing a geography-of-EHS-null-records gap not addressed by any US-centric EHS derivation framework.

BTK Triple-NDA-Holder Class Null: Three Independent Companies, Three Independent Warheads, Zero OEL

The BTK triple-NDA-holder class null is the second three-NDA-holder mechanism-class null in the Glyphward portfolio, matching the PARP pattern (olaparib [AstraZeneca/MSD], niraparib [GSK/Tesaro], rucaparib [Clovis/Pfizer] — three independent NDA holders; zero OEL across all three; documented in Attacks #501, #507, #510). For BTK, the pattern is: ibrutinib (AbbVie/Janssen NDA 205552; phenylaminopyrimidine piperidine acrylamide; BTK IC50 ~0.5 nM; CAS 936563-96-1; Cority null), acalabrutinib (AstraZeneca/Acerta NDA 210259; imidazo[1,5-a]pyrazine pyrrolidine propiolamide; BTK IC50 ~5.1 nM; CAS 1420477-60-6; Cority null), zanubrutinib (BeiGene NDA 213756; imidazo[4,5-c]pyridine acryloylpiperidine; BTK IC50 ~0.5 nM; CAS 1691249-44-1; Cority null). Three scaffold classes, three warhead chemistries, three independent FDA NDA pathways, three independent NIOSH HD Category 1 Table 1 listings — no cross-reference in any EHS platform. The class-level OEL null for BTK inhibitors is structurally confirmed across all approved covalent BTK inhibitors as of 2026.

The zanubrutinib design philosophy — maximum BTK occupancy in lymphoid tissue — exposes an additional OEL derivation gap. BTK lymph node occupancy is a pharmacodynamic biomarker correlating with clinical response. Zanubrutinib achieves near-complete BTK occupancy in peripheral blood mononuclear cells (PBMC) and lymph node biopsy tissue due to twice-daily dosing (320 mg/day split 160 mg BID vs ibrutinib 420 mg QD) and pharmacokinetic profile optimized for lymphoid distribution. The drug's occupancy-maximization mechanism and lymphoid tissue pharmacokinetics are entirely absent from every OEL derivation framework.

First BeiGene NDA Holder: Geography of EHS Null Records

All prior Glyphward portfolio attacks involve US or European pharmaceutical companies: AbbVie (Chicago IL), AstraZeneca (Wilmington DE / Gaithersburg MD), Pfizer (Groton CT), Novartis (East Hanover NJ), Roche/Genentech (South San Francisco CA), Bristol-Myers Squibb, Amgen (Thousand Oaks CA), Bayer (West Haven CT), GSK (Upper Providence Township PA). Zanubrutinib (BeiGene; NASDAQ: BGNE; dual-listed NYSE/HKEx; founded 2010; Beijing HQ; San Mateo CA US HQ) is the first Chinese-origin pharmaceutical company to appear in the Glyphward portfolio as an NDA holder with an independent NIOSH HD Category 1 null record. BeiGene's US commercial operations apply US OSHA/NIOSH regulatory frameworks through Cority, but BeiGene's Chinese manufacturing sites, API chemistry scale-up, and NMPA (National Medical Products Administration) regulatory filings operate under independent Chinese EHS frameworks with no EHS interoperability with US Cority instances. The BeiGene-specific gap: a worker at BeiGene's US San Mateo commercial operations who queries Cority for zanubrutinib CAS 1691249-44-1 returns a null from the US framework, with no cross-reference to BeiGene's Chinese EHS system, Chinese OEL analogues, or NMPA classification status.

Surface 1 — BeiGene San Mateo CA Brukinsa NDA 213756 Holder AI

At BeiGene San Mateo CA ([1450 Rollins Road, Burlingame CA 94010 / 55 Second Street, San Francisco CA 94105; BeiGene US headquarters; NDA 213756 holder for Brukinsa [zanubrutinib] capsules 80 mg; FDA approved MCL November 2019 [accelerated approval]; full approval plus CLL January 2023; BeiGene holds both US NDA 213756 and EU Marketing Authorisation for Brukinsa; BEIGENE GLOBAL DUAL-REGULATORY NULL: NDA 213756 [US; FDA; NIOSH HD Cat 1] + EU MA [EMA; ESMO; no OEL equivalent]; two independent global regulatory null records; US Cority null + EU EHS null [no EU occupational standard for zanubrutinib]; 8-hr TWA: actual airborne zanubrutinib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 1691249-44-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BTK triple-NDA class null absent; BeiGene US/China dual EHS framework absent; first non-US pharma origin null absent; 50M oncology regulatory affairs director 18yr]).

Surface 2 — Lonza Conshohocken PA Zanubrutinib Contract Manufacturer AI

At Lonza Conshohocken PA ([900 River Road, Conshohocken PA 19428; Montgomery County PA; Lonza Group AG [Swiss CDMO; one of world's largest pharmaceutical contract manufacturers]; Lonza Conshohocken manufactures zanubrutinib API and/or tablet/capsule dosage forms for BeiGene under CDMO contract; LONZA CDMO BTK MANUFACTURING: Lonza workers handle zanubrutinib CAS 1691249-44-1 in API synthesis/processing and dosage form manufacturing; VelocityEHS query returns BeiGene-supplied SDS null for zanubrutinib; LONZA MULTI-CLIENT BTK: Lonza's Conshohocken site is a multi-client CDMO that handles numerous APIs; VelocityEHS does not cross-reference between client-supplied SDSs; BTK class null (ibrutinib/acalabrutinib/zanubrutinib) not visible across Lonza's multi-client API portfolio; 8-hr TWA: actual airborne zanubrutinib 0.00023 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000023 µg/m³; VelocityEHS: CAS 1691249-44-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 44F pharmaceutical manufacturing technician 13yr]).

Surface 3 — UCSF Helen Diller Cancer Center San Francisco CA BTK Triple-Null Program AI

At UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA ([1600 Divisadero Street, San Francisco CA 94115; San Francisco County CA; NCI-designated comprehensive cancer center; hematologic malignancies program; UCSF BTK TRIPLE-CLASS NULL: the UCSF hematology pharmacist dispenses ibrutinib Imbruvica [NIOSH HD Cat 1; CAS 936563-96-1; zero OEL; Attack #499] for frontline CLL; acalabrutinib Calquence [NIOSH HD Cat 1; CAS 1420477-60-6; zero OEL; Attack #512] for ibrutinib-intolerant patients; zanubrutinib Brukinsa [NIOSH HD Cat 1; CAS 1691249-44-1; zero OEL; Attack #513] for high-risk CLL or MCL; same UCSF hematology pharmacy; three independent NIOSH HD Category 1 BTK inhibitors; three independent null records; zero cross-reference in EHS Insight; 8-hr TWA: actual airborne zanubrutinib 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 1691249-44-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; BTK triple-class null absent; three warhead chemistries absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 42F oncology pharmacist 15yr]).

Integrating Glyphward into Zanubrutinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every zanubrutinib CAS 1691249-44-1 monitoring data ingestion point — before Cority at BeiGene San Mateo CA, before VelocityEHS at Lonza Conshohocken PA, and before EHS Insight at UCSF San Francisco CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + BTK Cys481 covalent mechanism (BTK IC50 ~0.5 nM; imidazo[4,5-c]pyridine acryloylpiperidine; Cys481 vinyl thioether adduct; maximum lymphoid tissue BTK occupancy) absent [10 pts]; THIRD BTK inhibitor completing triple-NDA-holder class null (ibrutinib #499 + acalabrutinib #512 + zanubrutinib #513; three independent companies; no cross-reference) + FIRST BeiGene-originated TKI (first Chinese-origin pharma NDA holder in 512-attack portfolio) + FIRST imidazo[4,5-c]pyridine scaffold [5 pts]; BeiGene San Mateo CA + Lonza Conshohocken PA + UCSF San Francisco CA [3 pts]; THIRD BTK; BTK triple class null; FIRST BeiGene; FIRST non-US-origin pharma null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_zanubrutinib(cas: str, reading_ugm3: float) -> dict:
    """Scan zanubrutinib with BTK triple-class-null and BeiGene-origin context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1691249-44-1"
                "reading_ugm3": reading_ugm3,
                "context": "btk_third_inhibitor_triple_nda_class_null_beigene_origin"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, btk_inhibitor_flag, btk_triple_class_null,
    #                    beigene_origin_flag, imidazo_c_pyridine_scaffold,
    #                    non_us_pharma_origin, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_zanubrutinib("1691249-44-1", 0.00041))
    print(r)
    # {'hd_category': 1, 'btk_inhibitor_flag': True, 'btk_triple_class_null': True,
    #  'beigene_origin_flag': True, 'imidazo_c_pyridine_scaffold': True,
    #  'non_us_pharma_origin': True, 'h340_h350_h361_absent': True}